Sanofi (NASDAQ:SNY) Shares Sold by First Horizon Advisors Inc.

First Horizon Advisors Inc. trimmed its position in shares of Sanofi (NASDAQ:SNY) by 6.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,919 shares of the company’s stock after selling 456 shares during the quarter. First Horizon Advisors Inc.’s holdings in Sanofi were worth $334,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Abel Hall LLC raised its stake in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares in the last quarter. PDS Planning Inc grew its position in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after buying an additional 200 shares in the last quarter. Financial Advocates Investment Management grew its position in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares in the last quarter. Angeles Investment Advisors LLC increased its stake in shares of Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after buying an additional 210 shares during the period. Finally, Keudell Morrison Wealth Management raised its holdings in Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after acquiring an additional 217 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 2.1 %

SNY opened at $54.89 on Wednesday. The stock has a market capitalization of $139.30 billion, a P/E ratio of 22.04, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The business has a 50 day simple moving average of $51.22 and a 200-day simple moving average of $52.56. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Sanofi presently has an average rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.